Healthcare
Brainsway Ltd.(BRSYF)
Live Price
Offline$16.84
+0.00% today
1Y Change
+395.29%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $660.00M
- Revenue Growth
- +37.8%
- EPS Growth
- +155.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Brainsway Ltd. (BRSYF) is a Healthcare stock with a market cap of $660.00M and listed on OTC. The stock last traded around $16.84 and up 395.3% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +37.8%, EPS growth of +155.8%, a dividend yield of 0.0%. What stands out right now is revenue +37.8%, EPS +155.8%, free cash flow +170.8% with operating margin 8.3% and ROIC 5.0%. Valuation already assumes a fairly strong business story at P/E 82.2 and price/sales 11.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BRSYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+37.8% vs +7.6% peer median
Operating Margin
Below sector median
+8.3% vs +19.4% peer median
P/E
Above sector median
82.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +37.8% and EPS at +155.8%, with operating margin around 8.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 9, 2026 | โ | +0.0% | +0.0% | +14.2% |
2025 Aug 13, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
BRSYF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BRSYF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BRSYF Max Drawdown
-19.03%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for BRSYF and SPY.
Company Overview
Brainsway Ltd.
OTC
Brainsway Ltd. is a pioneering medical device company that focuses on the development and distribution of advanced brain stimulation solutions. Its primary function is to provide non-invasive treatments for a variety of neuropsychiatric disorders, including depression and obsessive-compulsive disorder (OCD), using Deep Transcranial Magnetic Stimulation (Deep TMS) technology. This technology is known for targeting deeper and broader brain regions compared to traditional TMS, offering potential therapeutic benefits with minimal side effects. Brainsway Ltd. serves a diverse healthcare sector, including hospitals, clinics, and private practices. The company's innovative technology is significant in the medical device market, emphasizing a shift towards non-pharmacological treatment options and setting a precedent for future neurological therapies. Founded in 2003 and based in Israel, Brainsway Ltd. remains at the forefront of improving mental health treatments globally.
- Employees
- 129
- Street Address
- 16 Hartum St, Har Hotzvim
- Mailing
- Jerusalem, 9777516
- Region
- Jerusalem, Israel
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 82.2
- EV/EBITDA
- 94.0
- Price/Sales
- 11.6
- Price/Book
- 8.6
Growth
- Revenue
- +37.8%
- EPS
- +155.8%
- Free Cash Flow
- +170.8%
Profitability
- Gross Margin
- 75.4%
- Operating Margin
- 8.3%
- Net Margin
- 13.5%
- ROE
- 11.1%
- ROIC
- 5.0%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 3.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.